

Piqray[®] (alpelisib) – Expanded indication

- On January 18, 2024, the [FDA approved](#) Novartis' [Piqray \(alpelisib\)](#), in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
 - Piqray was previously approved for this indication in post-menopausal women and men. This approval expands its use to include pre and perimenopausal women.
- The recommended dose of Piqray for the treatment of breast cancer is 300 mg (two 150 mg film-coated tablets) orally once daily. Treatment should continue until disease progression or unacceptable toxicity occurs.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.